Stopfer, Peter

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 349

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 234

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 206

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Stopfer, P., Marzin, K., Narjes, H., Gansser, D., Shahidi, M., Uttereuther-Fischer, M., & Ebner, T. (2012) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismHER2/EGFR in Cancer Research

Cited by 137

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., & Stopfer, P. (2013) · Clinical Pharmacokinetics

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 94

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Wind, S., Giessmann, T., Jungnik, A., Brand, T., Marzin, K., Bertulis, J., Hocke, J., Gansser, D., & Stopfer, P. (2014) · Clinical Drug Investigation

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 63

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Schnell, D., Buschke, S., Fuchs, H., Gansser, D., Goeldner, R.-G., Uttenreuther-Fischer, M., Stopfer, P., Wind, S., Petersen-Sylla, M., Halabi, A., et al. (2014) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismHER2/EGFR in Cancer Research

Cited by 44